Medicare Faces $336M Waste from Lecanemab Vial Sizes in Alzheimer's Treatment
核心洞察
Analysis reveals Medicare (搜索) could waste up to $336 million annually on discarded lecanemab (Leqembi) due to inefficient vial sizing, affecting patients with mild cognitive impairment (搜索) and dementia (搜索).
Researchers identify potential savings of up to 74% through optimized vial sizes, suggesting a 250mg vial could reduce waste by $61-155 million without compromising care quality.
Despite waste reduction possibilities, concerns persist about lecanemab's modest clinical efficacy, safety profile, and overall Medicare (搜索) spending of up to $5 billion annually for patient treatment.
A new analysis published in JAMA Internal Medicine reveals significant Medicare (搜索) waste associated with lecanemab (Leqembi) administration, projecting annual losses between $133 million and $336 million due to unusable leftover medication from single-use vials.
The study examined 1,490 Medicare (搜索) beneficiaries aged 65 and older who could potentially receive lecanemab treatment for mild cognitive impairment (搜索) or mild dementia (搜索). The analysis focused on the drug's weight-based dosing protocol of 10 mg/kg, currently available only in 200mg and 500mg single-use vials.
Weight-Based Analysis Reveals Systematic Waste
Researchers categorized patients into 13 weight ranges, with the majority falling between 60-90kg. The study found striking variations in waste across weight categories. Patients in higher weight ranges experienced minimal waste (11mg per dose), while others faced up to 62mg of waste per dose, translating to annual per-person waste between $375 and $2,044.
Potential Solutions Through Vial Size Optimization
Through 189 simulations of alternative vial configurations, researchers identified significant opportunities for waste reduction. Replacing one 500mg vial with a 250mg option could save $61-155 million annually. Additional savings of $99-251 million might be achieved by introducing a 75mg vial size for cases requiring three vials.
Broader Economic and Clinical Implications
While the waste reduction potential is significant, it represents only a fraction of Medicare (搜索)'s projected $5 billion annual spending on lecanemab treatment, which includes drug costs, specialist visits, and required testing. The medication, approved by the FDA in 2023, faces ongoing scrutiny regarding its clinical value and safety profile.
Regulatory and Policy Considerations
Current legislation requires manufacturers to reimburse Medicare (搜索) only for waste exceeding 10%. The study authors suggest that vial size optimization could reduce wasteful spending by up to 74% without impacting care quality or triggering price increases under the Inflation Reduction Act's restrictions.
The findings come amid broader debates about lecanemab's role in Alzheimer's (搜索) treatment, particularly following its rejection by the European Medicines Agency (搜索) in July 2024. Critics suggest that resources might be better directed toward prevention efforts, including hearing loss management and lifestyle interventions that address modifiable dementia (搜索) risk factors.